A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2016
At a glance
- Drugs Lucitanib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors Clovis Oncology
- 04 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 04 Apr 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 04 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.